Pharsight

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8685444	ALPHARMA PHARMS	Sequestering subunit and related compositions and methods	Jul, 2025 (1 year, 2 months from now)
US8685443	ALPHARMA PHARMS	Sequestering subunit and related compositions and methods	Jul, 2025 (1 year, 2 months from now)
US8877247	ALPHARMA PHARMS	Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist	Jun, 2027 (3 years from now)
US8158156	ALPHARMA PHARMS	Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist	Jun, 2027 (3 years from now)
US8846104	ALPHARMA PHARMS	Pharmaceutical compositions for the deterrence and/or prevention of abuse	Jun, 2027 (3 years from now)
US7682634	ALPHARMA PHARMS	Pharmaceutical compositions	Jun, 2027 (3 years from now)
US7682633	ALPHARMA PHARMS	Pharmaceutical composition	Jun, 2027 (3 years from now)
US7815934	ALPHARMA PHARMS	Sequestering subunit and related compositions and methods	Dec, 2027 (3 years from now)
US8623418	ALPHARMA PHARMS	Pharmaceutical composition	Nov, 2029 (5 years from now)

Embeda is owned by Alpharma Pharms.

Embeda contains Morphine Sulfate; Naltrexone Hydrochloride.

Embeda has a total of 9 drug patents out of which 0 drug patents have expired.

Embeda was authorised for market use on 13 August, 2009.

Embeda is available in capsule, extended release;oral dosage forms.

Embeda can be used as management of pain severe enough to require daily, around-the-clock, long term opioid treatment by orally administering a plurality of composite subunits as claimed, treatment of moderate to severe chronic pain by administering an intact composition as claimed, management of pain severe enough to require daily, around-the-clock, long term opioid treatment by orally administering an intact composition as claimed..

The generics of Embeda are possible to be released after 07 November, 2029.

Drug Exclusivity	Drug Exclusivity Expiration
New Combination(NC)	Aug 13, 2012

Drugs and Companies using MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 13 August, 2009

Treatment: Management of pain severe enough to require daily, around-the-clock, long term opioid treatment by orally administering a plurality of composite subunits as claimed; Management of pain severe enough t...

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

Strength	Submission Date	ANDA(s) Filed	Last patent expiry	180 day status
20 mg/0.8 mg	16 Aug, 2018	1	07 Nov, 2029	Extinguished
100 mg/4 mg	03 May, 2010	1	19 Jun, 2027	Extinguished
60 mg/2.4 mg	25 May, 2010	1	19 Jun, 2027	Extinguished
30 mg/1.2 mg 50 mg/2 mg 80 mg/3.2 mg	28 May, 2010	1	19 Jun, 2027	Extinguished

Strength	Dosage	Availability
50MG;2MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE, EXTENDED RELEASE;ORAL	Discontinued
30MG;1.2MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE, EXTENDED RELEASE;ORAL	Discontinued
20MG;0.8MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE, EXTENDED RELEASE;ORAL	Discontinued
80MG;3.2MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE, EXTENDED RELEASE;ORAL	Discontinued
100MG;4MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE, EXTENDED RELEASE;ORAL	Discontinued
60MG;2.4MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE, EXTENDED RELEASE;ORAL	Discontinued

Pharsight

Embeda patents expiration

EMBEDA family patents

Related content